A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation
and Literature Review.
10.3779/j.issn.1009-3419.2023.102.36
- Author:
Yongen MIAO
1
;
Yukun WANG
1
;
Ping LI
1
;
Min TAN
1
;
Tingting WEN
1
;
Changhui WANG
1
;
Shuanshuan XIE
1
Author Information
1. Department of Respiratory and Critical Care Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China.
- Publication Type:Review
- Keywords:
Afatinib;
Compound variants;
Epidermal growth factor receptor;
L833V/H835L;
Lung neoplasms
- MeSH:
Humans;
Adenocarcinoma of Lung/genetics*;
Carcinoma, Non-Small-Cell Lung/pathology*;
ErbB Receptors/genetics*;
Lung Neoplasms/pathology*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2023;26(10):795-800
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor (EGFR) mutations are the most common driver genes in the development of non-small cell lung cancer (NSCLC), of which mutations in exons 18-21 are frequent, especially the loss of exon 19 and exon 21 L858R mutation are the most frequent. Other rare gene mutations are rare. Simultaneous occurrence of two or more rare EGFR mutations are extremely rare in lung cancer, and the incidence of EGFR L833V/H835L rare gene compound mutations is very low, and there is little clinical data and evidence of relevant treatment methods. Some EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are effective in treating lung cancer patients with rare gene mutations. In this article, we reported a case of NSCLC patient with a rare gene compound mutation EGFR L833V/H835L, who responded to Afatinib in combination with Anilotinib treatment well after 5 months of treatment, and computed tomography (CT) showed shrinkage of lung lesions. Meanwhile, we also compiled previously reported NSCLC patients with EGFR L833V/H835L rare gene compound mutation and summarized the characteristics of this group of patients and the effect of applying different kinds of EGFR-TKIs treatment.
.
